Mangafodipir
Phase 2Small molecule
Mangafodipir is one of 97 small molecule programs targeting Neurotoxicity. It is currently in Phase 2.
3
Indications
5
Total Trials
1
Active Trials
96
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
560 competitors in Multiple Sclerosis
#DrugCompanyPhaseTrials
1Betaseron
BayerPreclinical
Kesimpta
NovartisPreclinical
Tysabri
BiogenPreclinical
Avonex
EMD SeronoPreclinical
Campath
GGenzyme, a Sanofi Company
Preclinical
Flomax
SanofiPreclinical
Mangafodipir
EEgetis Therapeutics
Phase 2
Pred Forte
NovartisPreclinical
Myfortic
NovartisPreclinical
Novantrone
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Sclerosis1 trial
Manganese-Enhanced Magnetic Resonance Imaging in Healthy Volunteers and People With Multiple Sclerosis
Completed·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 1·NCT01326715·17 enrolled
Chemotherapy1 trial
Percutaneous Coronary Intervention1 trial
Epilepsy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Mangafodipir. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- EEgetis Therapeutics